Story perspectives

PhRMA CEO Steve Ubl to Depart After Decade of Leadership

4/9/2026

Summary

Story summary

Steve Ubl, the Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), will step down at the end of 2026 after leading the organization for more than a decade.
His tenure included navigating the COVID-19 pandemic and bipartisan pressure to lower drug prices.
Under his leadership, PhRMA supported reforms tied to the Inflation Reduction Act, which allowed Medicare to negotiate drug prices.
His departure leaves a leadership gap amid ongoing scrutiny from the Trump administration and internal divisions within the industry.
PhRMA will begin searching for a successor, with Lori Reilly emerging as a potential candidate.

History

Historical Context

The Inflation Reduction Act, signed into law on August 16, 2022, marked a pivotal change in U.S. healthcare policy by allowing Medicare to negotiate drug prices. This legislation emerged amid rising public demand for affordable medications, with 18% of Americans unable to afford prescriptions. The act reflects ongoing debates about healthcare costs and industry accountability, particularly under the scrutiny of the Trump administration.

1 of 2

Story summary

Steve Ubl, the Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), will step down at the end of 2026 after leading the organization for more than a decade.
His tenure included navigating the COVID-19 pandemic and bipartisan pressure to lower drug prices.
Under his leadership, PhRMA supported reforms tied to the Inflation Reduction Act, which allowed Medicare to negotiate drug prices.
His departure leaves a leadership gap amid ongoing scrutiny from the Trump administration and internal divisions within the industry.
PhRMA will begin searching for a successor, with Lori Reilly emerging as a potential candidate.

1 / 2